XML 228 R20.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates as one operating segment, the research and development of its investigational drug product. The Company used the management approach to determine its reportable operating segment. The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer, who reviews financial information presented on a consolidated basis. The Company is a clinical-stage pharmaceutical company and has limited revenue associated with a license and collaboration agreement. The CODM uses net loss as a measure of profit and loss, and assesses Company performance through the achievement of its clinical development goals. The CODM is regularly provided with budgeted and forecasted expense information which is used to determine the Company’s liquidity needs and cash allocation to its development programs. The CODM uses cash and marketable securities as a measure of segment assets in managing the enterprise.
The Company had revenue of $1.0 million during the year ended December 31, 2024, related to its Exclusive License and Collaboration Agreement with Kuva Labs (Note 17) who is based in the United States . The Company had no revenue during the year ended December 31, 2023. Depreciation and amortization expense was $0.2 million and $0.2 million for the years ended December 31, 2024, and 2023, respectively. Equity method investment expense was $0.1 million for the year ended December 31, 2024. There was no equity method investment expense for the year ended December 31, 2023.
The following table illustrates our segment information for significant operating expenses and includes a reconciliation to net loss for the years ended December 31, 2024 and 2023:

 Year Ended December 31,
 20242023
Revenue$1,000 $— 
Operating Expenses:
Research and development by significant expense:
  BOLSTER trial3,581 3,517 
  ASCEND trial754 1,155 
  Chemistry, manufacturing and controls2,035 2,406 
  Clinical department4,304 4,744 
  Other (1)
660 912 
Research and development11,334 12,734 
General and administrative by significant expense:
  Corporate3,693 3,856 
  Investor relations/public relations/communications1,332 898 
  Finance2,265 2,421 
  Legal1,284 1,292 
  Business development582 1,474 
  Share based compensation expense1,383 1,497 
  Other (2)
1,536 1,536 
General and administrative12,075 12,974 
Operating loss(22,409)(25,708)
Other income (expense),net1,626 2,538 
Benefit from income taxes(798)(2,330)
Net loss$(19,985)$(20,840)
Cash and marketable securities$31,245 $50,535 
 (1) Included in other are GBM study, FORTIFIDE study and research
     oncology expenses
 (2) Included in other are facilities expense, human resource
     and information technology expenses